Bile acid metabolism and signaling in health and disease: molecular mechanisms and therapeutic targets

被引:11
|
作者
Fleishman, Joshua S. [1 ]
Kumar, Sunil [1 ]
机构
[1] St Johns Univ, Coll Pharm & Hlth Sci, Dept Pharmaceut Sci, Queens, NY 11439 USA
关键词
FARNESOID-X-RECEPTOR; VITAMIN-D-RECEPTOR; SMALL HETERODIMER PARTNER; GROWTH-FACTOR; 19; HUMAN COLON-CANCER; NF-KAPPA-B; YIN YANG 1; MUSCARINIC ACETYLCHOLINE-RECEPTOR; 12-ALPHA-HYDROXYLASE GENE CYP8B1; ENDOPLASMIC-RETICULUM STRESS;
D O I
10.1038/s41392-024-01811-6
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Bile acids, once considered mere dietary surfactants, now emerge as critical modulators of macronutrient (lipid, carbohydrate, protein) metabolism and the systemic pro-inflammatory/anti-inflammatory balance. Bile acid metabolism and signaling pathways play a crucial role in protecting against, or if aberrant, inducing cardiometabolic, inflammatory, and neoplastic conditions, strongly influencing health and disease. No curative treatment exists for any bile acid influenced disease, while the most promising and well-developed bile acid therapeutic was recently rejected by the FDA. Here, we provide a bottom-up approach on bile acids, mechanistically explaining their biochemistry, physiology, and pharmacology at canonical and non-canonical receptors. Using this mechanistic model of bile acids, we explain how abnormal bile acid physiology drives disease pathogenesis, emphasizing how ceramide synthesis may serve as a unifying pathogenic feature for cardiometabolic diseases. We provide an in-depth summary on pre-existing bile acid receptor modulators, explain their shortcomings, and propose solutions for how they may be remedied. Lastly, we rationalize novel targets for further translational drug discovery and provide future perspectives. Rather than dismissing bile acid therapeutics due to recent setbacks, we believe that there is immense clinical potential and a high likelihood for the future success of bile acid therapeutics.
引用
收藏
页数:51
相关论文
共 50 条
  • [31] Signaling pathways in Parkinson’s disease: molecular mechanisms and therapeutic interventions
    Xu Dong-Chen
    Chen Yong
    Xu Yang
    ShenTu Chen-Yu
    Peng Li-Hua
    [J]. Signal Transduction and Targeted Therapy, 8
  • [32] Signaling pathways in Parkinson's disease: molecular mechanisms and therapeutic interventions
    Xu, Dong-Chen
    Yong, Chen
    Yang, Xu
    Chen-Yu, ShenTu
    Peng, Li-Hua
    [J]. SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2023, 8 (01)
  • [33] VARIOUS MECHANISMS AFFECTING BILE ACID METABOLISM
    BERGSTROM, S
    [J]. BIOCHEMICAL PHARMACOLOGY, 1961, 8 (01) : 86 - &
  • [34] Molecular Mechanisms of Emerging Therapeutic Targets in Alzheimer's Disease: A Systematic Review
    Premkumar, T.
    Lulu, S. Sajitha
    [J]. NEUROCHEMICAL JOURNAL, 2022, 16 (04) : 443 - 455
  • [35] Molecular Mechanisms of Emerging Therapeutic Targets in Alzheimer’s Disease: A Systematic Review
    T. Premkumar
    S. Sajitha Lulu
    [J]. Neurochemical Journal, 2022, 16 : 443 - 455
  • [36] Podocyte Death in Diabetic Kidney Disease: Potential Molecular Mechanisms and Therapeutic Targets
    Zhong, Suye
    Wang, Na
    Zhang, Chun
    [J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2024, 25 (16)
  • [37] Molecular mechanisms of Alzheimer's disease: From therapeutic targets to promising drugs
    Alan, Elif
    Kerry, Zeliha
    Sevin, Gulnur
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2023, 37 (03) : 397 - 427
  • [38] Molecular mechanisms and therapeutic targets in steatosis and steatohepatitis
    Anderson, Nora
    Borlak, Juergen
    [J]. PHARMACOLOGICAL REVIEWS, 2008, 60 (03) : 311 - 357
  • [39] Editorial: The molecular mechanisms and therapeutic targets of atherosclerosis
    Gualtierotti, Roberta
    Ruscica, Massimiliano
    [J]. FRONTIERS IN CARDIOVASCULAR MEDICINE, 2023, 9
  • [40] Autophagy in health and disease: From molecular mechanisms to therapeutic target
    Lu, Guang
    Wang, Yu
    Shi, Yin
    Zhang, Zhe
    Huang, Canhua
    He, Weifeng
    Wang, Chuang
    Shen, Han-Ming
    [J]. MEDCOMM, 2022, 3 (03):